Oncovaccine CaTeVac has undergone preclinical studies and will begin to be used in 2027.
Deputy Prime Minister Tatiana Golikova announced the completion of preclinical studies of the CaTeVac vaccine for dendritic cell cancer for the treatment of several types of cancer; The drug will start to be used next year. "Preclinical studies have been successfully completed, documents are being prepared to obtain approval for the production and clinical use of the CaTeVac dendritic cell cancer vaccine," Golikova said at the meeting of the project committee of the national project "New Technologies for Health Savings".